Register your practice, schedule a sales rep visit, or order support materials with FIRMAGON Connect.

Sign Up Now

FIRMAGON® is approved for all stages of ADVANCED PROSTATE CANCER (APC)

Range of advanced prostate cancer (APC) stages

≈60% OF PATIENTS IN THE CLINICAL TRIAL HAD LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER2

The pivotal CS21 study included men aged ≥18 years with histologically confirmed adenocarcinoma of the prostate (all stages), for whom endocrine treatment was indicated (except for neoadjuvant therapy).2

In the clinical trials, these categories were classified as “other.”2

START FIRMAGON® TODAY

2014: >16,500 patients started on FIRMAGON
3
2015: >10% increase in starts over 20143

{{patient.name}}

{{patient.subheading}}

{{patient.alttext}}

Monthly Matters

Help make the most of your patient's treatment experience

Make the most of monthly visits. Help your patients feel connected to their therapy through the reassurance of regular treatment and progress check-ins. Ferring is here to help enhance this connection at every step.
One-month depot is ideal for my patients. They love to come in, get checked, and see their nurse practitioner to ask questions and get updated data about their condition.
Actual physician quote

Abbreviations: ADT = androgen deprivation therapy; APC = advanced prostate cancer; PSA = prostate-specific antigen.

REFERENCES: 1. FIRMAGON® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.2. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538.3. Data on file. Ferring Pharmaceuticals Inc.